Presentation (CTI)

OBJECTIVES: Myelofibrosis (MF) is a severe hematologic malignancy in which anaemia is a common manifestation that worsens over time, leading to increased transfusion dependence, reduced quality-of-life and poor survival. This study aimed to estimate the budget impact of momelotinib versus ruxolitinib, from a Swedish payer perspective over 3 years (base year 2025), in patients with MF and moderate to severe anaemia (Hb<10g/dL), including anaemia-related treatments.
METHODS: The number of patients with MF receiving JAKi treatment (any line), and the proportion with anaemia, were identified using Swedish registry data. Costs included drug acquisition (JAKi and erythropoietin [EPO]) and blood transfusions, as these were expected to differ between treatments. Anaemia-related resource use was informed by clinical expert opinions. Patients with moderate anaemia were assumed to receive weekly EPO during the first year, while patients with severe anaemia were assumed to receive monthly transfusions throughout the 3-year time horizon. All patients were assumed to receive JAKi treatment over the full time horizon, while patients with mild anaemia (Hb≥10 to <12g/dL) were assumed not to receive anaemia-related treatment. Unit costs were obtained from publicly available Swedish sources and expressed in 2025 SEK. Costs beyond year 1 were discounted at 3% annually.
RESULTS: Overall, 183 patients with MF filled a prescription for a JAKi in Sweden in 2025. Of these, 39 (21%) patients were assumed to have moderate or severe anaemia. Treatment with momelotinib was associated with cost savings of approximately SEK 3.0 million in the first year compared with ruxolitinib, primarily driven by reduced EPO use. Total discounted cost savings were estimated at approximately SEK 4.0 million over 3 years.
CONCLUSIONS: In this budget impact analysis, treatment with momelotinib was associated with cost savings compared with ruxolitinib for patients with MF and moderate to severe anaemia. Funding: GSK